Enveda is a clinical-stage biotechnology company that learns from life’s chemistry to create small-molecule therapeutics using AI-powered metabolomics and a proprietary chemical sequencer. The platform makes previously inaccessible natural chemistry searchable and uses automation to map therapeutic properties at high throughput. Enveda says it delivers 12+ development candidates 4× faster and 10× cheaper than industry averages and has built one of the world’s largest collections of natural samples. Its pipeline includes sixteen preclinical programs, more than a dozen development candidates, four IND-enabling programs, and one clinical program. ENV-294, the lead program, is a first-in-class oral anti-inflammatory small molecule discovered on the platform and has moved into a Phase 1b trial after favorable Phase 1a results; Enveda has enrolled the first patient. The company recently raised additional capital and added industry veteran Dr. Mikael Dolsten to its board to support clinical advancement across atopic dermatitis, asthma, inflammatory bowel disease, obesity, and other indications. Enveda harnesses AI-powered tools to identify and characterize molecules produced by living organisms, building a database of chemical biodiversity it calls the library of life. Its platform integrates computational methods with deep chemical and biological insights to uncover novel mechanisms of action and drug candidates. The company has advanced ENV-294, a first-in-class molecule for atopic dermatitis and asthma, into clinical trials and highlights the potential for a safe, effective oral therapy in immunology and inflammation. Enveda plans to expand its clinical pipeline in 2025 and further enhance its AI-driven discovery capabilities. The company frames its approach as metabolite-driven drug development aimed at delivering medicines faster by learning from evolved solutions in nature. Enveda is a biotechnology company that uses an AI-powered platform combining metabolomics, machine learning, and automated high-throughput laboratory workflows to translate natural compounds into drug candidates. Its platform has characterized the structure and function of over 1 million natural compounds, creating the largest known natural product dataset custom-built for modern drug discovery. The company says this approach answers what molecules are and what they do at scale and enables discovery roughly four times faster than historical averages. Enveda’s pipeline includes 10 Development Candidates across immunology & inflammation, obesity, fibrosis, and neurosensory indications. The company recently received IND clearance for ENV-294, which entered Phase I at the end of October. The new funding will support multiple clinical catalysts in 2025 and 2026 and further investment in the platform and discovery programs. Enveda Biosciences, founded in 2019 and based in Boulder, Colorado, combines AI with ethnobotanical knowledge to identify medicinal molecules from plants. The company has assembled a database of about 38,000 medicinal plants linked to roughly 12,000 diseases and symptoms. Using a transformer model that deciphers the "chemical language" of whole samples, Enveda prioritizes sets of molecules for development rather than studying single compounds in isolation. That platform has produced near-term assets: two drugs (one for skin conditions including eczema, and one for inflammatory bowel diseases) are expected to enter clinical trials later this year. Financially, the company has raised capital that totals $230 million to date and plans to pursue a Series C after the start of those clinical trials. Enveda builds a proprietary platform that combines large language models, metabolomics, and robotics to create a high-resolution chemical map of nature and search nature’s chemical space for drug discovery. The platform addresses long-standing obstacles in natural product drug development, including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access. Enveda pairs this technology with experienced drug hunters and data scientists to advance platform-derived molecules. The company plans to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications. Financially, Enveda has been raising growth capital to advance its pipeline and platform and recently completed additional financing to support clinical progress. For more information, Enveda directs readers to envedabio.com.

Total raised

$660M

Funding rounds

9

Latest round

Series D

Latest activity

Sep 2025